NCT06940947RecruitingPhase 3
Endoscopic Therapy Or Surgery for Early Colon Cancer
Endoscopic THerapy Or Surgery for Early Colon Cancer (ETHOS)
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
The trial is a randomized head-to-head comparison of the benefits, harms and burdens of endoscopic full-thickness resection (eFTR), a novel, minimally invasive endoscopic treatment modality, for early colon cancer as compared to standard-of-care surgery.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 434 (estimated)
- First submitted
- 15 Apr 2025
- Start date
- 25 Aug 2025
- Primary completion date
- 1 Sept 2033
- Lead sponsor
- Norwegian Department of Health and Social Affairs
- Diseases
- Colorectal cancer, Childhood cancers
- NCT number
- NCT06940947
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 434
- From 25 Aug 2025 to the primary completion date, 1 Sept 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Newly diagnosed biopsy-confirmed colon cancer (adenocarcinoma) with macroscopic suspicion of submucosal invasion considered removable by EFTR as deemed by the local multidisciplinary team (MDT) at the participating center
- Size ≤20 mm in diameter as deemed by the colonoscopist
- No presence of histopathological high-risk features in biopsy (high grade tumor growth, budding grade 2 or 3, or lymphovascular invasion)
- Patient eligible for surgical removal as deemed by the local MDT at the participating center
- Endoscopic images or video of the tumor
- No sign of disease beyond T2N0M0 on pre-treatment imaging, biopsy sampling, and radiographic and clinical evaluation
- No contraindication for any of the two treatment arms
- Written informed consent
- No prior or synchronous CRC
- No other malignancy which is not cured
- No more than 10 adenomas or serrated polyps
- No genetic cancer syndrome (adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome)
- No inflammatory bowel disease
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University Of Gdansk Coordinator of this site? Confirm its status | Gdansk | Poland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.